January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 


Cambridge Healthtech Institute’s
Membrane Proteins
A Valuable Resource and Target
January 21-22, 2015

Membrane proteins are the gateways to the cell and are valuable drug targets. For researchers to design better-targeted drugs, they need to know their structure and functional characteristics. However, determining these characteristics is difficult, because researchers need large amounts of membrane protein to characterize their functions and map their structures. Sources are scarce due to the practical problems of working with membrane proteins—specifically, difficulties in expression, purification and crystallization. Cambridge Healthtech Institute’s Membrane Proteins conference addresses the strategies and solutions for their extraction, expression and purification, and features case studies showcasing their value as an antibody drug target. Join the in-depth exploration of how to obtain functional membrane proteins, and learn more about this important protein class.

Day 1 | Day 2 | Download Brochure | Speaker Biographies 

Final Agenda 


1:30 pm Conference Registration

BUZZ Sessions png

2:00 BuzZ Session A

3:00 Refreshment Break in the Exhibit Hall with Poster Awards

3:45 BuzZ Session B
(More Details >>)

4:30-5:00 Short Course Registration

5:00-8:00 Dinner Short Courses More Details >> 


7:30 am Conference Registration and Morning Coffee


8:15 Chairperson’s Opening Remarks

William GilletteWilliam Gillette, Ph.D., Senior Scientist, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research

Keynote Presentation

8:20 The Distinct Issues of Membrane Proteins versus Soluble Proteins

RobertStroudRobert Stroud, Ph.D., Professor, Biochemistry/Biophysics and Pharmaceutical Chemistry; Director, Membrane Protein Expression Center, University of California at San Francisco (UCSF)

Membrane proteins present distinct issues versus soluble proteins; pure, homogeneous and stable in solution. Eukaryotic proteins need expression in eukaryotic cells. These include yeast, and insect cells. Human proteins, to be expressed for antibody preparation, require proper tailoring and glycosylation; and can often be achieved only in human cells. Antibody partners can be the basis for proof of principle therapeutics, and for helping to purify, assay, and validate membrane proteins’ mechanisms.

9:00 Expression of Transmembrane Proteins in Yeast for Genetic, Biochemical and Structural Studies

MarkDumontMark E. Dumont, Ph.D., Professor, Biochemistry and Biophysics, University of Rochester Medical Center

The difficulty of expression, solubilization, and purification of transmembrane proteins, particularly those from eukaryotes, constitutes a significant barrier to understanding their mechanisms. The use of a system based on expression of membrane proteins from various sources in baker’s yeast has allowed the use of genetic approaches for functional characterization and stabilization of expressed proteins, while facilitating purification of transmembrane enzymes, transporters, and receptors for biochemical studies and x-ray crystallographic structure determination.

9:30 Overproduction and Functional Characterization of Purified Equilibrative Nucleoside Transporters

 Franklin A. HaysFranklin A. Hays, Ph.D., Assistant Professor, Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center

The Solute Carrier Superfamily proteins constitute a functionally and structurally diverse family in eukaryotic membrane proteomes and are associated with modulating efficacy for an equally broad range of human therapeutics. Our recent focus is on defining the molecular basis for Equilibrative Nucleoside Transporter (ENT) inhibition, transport, and substrate recognition. ENTs have only been identified in eukaryotic organisms and have proven recalcitrant to overexpression and functional characterization in purified form - this despite the fact that they directly bind or transport over 25 FDA approved therapeutics. We have developed an optimized pipeline for the production of active, pure, eukaryotic ENTs and have used this system to obtain novel insights into the transport characteristics of the only identified ENT protein from Saccharomyces cerevisiae named Function Unknown Now 26 (FUN26). This talk will focus on our efforts to overproduce, purify, solubilize, and reconstitute functional ENT proteins along with novel insights into ENT transport properties.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 GPCR Purification: Protein Engineering and Process Optimisation are Key Elements for Successful GPCR Crystallisation

Markus KoglinMarkus Koglin, Ph.D., Associate Director, Protein Engineering, Heptares Therapeutics

The generation of Stabilised G-protein Coupled Receptors (StaRs) has opened new routes in the purification procedures for GPCRs. Here we demonstrate that protein quality is drastically improved with increasing thermostability. StaR generation alone normally does not provide suitable material for crystallisation. The combination of StaR technology, systematic construct design, and careful optimisation of the purification process delivers a powerful approach to generate protein with suitable crystallisation qualities.

11:20 Strategies for Detergent Stabilization and Large-Scale Affinity Purification of the Functional G Protein-Coupled Receptors

AlexeiYeliseevAlexei Yeliseev, Ph.D., Staff Scientist, Group Leader, LMBB, NIAAA, National Institutes of Health (NIH)

Human cannabinoid receptor CB2, a G protein-coupled receptor involved in regulation of immune response, is an important target for pharmaceutical drug development. For high resolution structural studies, milligram quantities of pure, homogenous and functional protein are required. We expressed the functional CB2 receptor in E. coli, and optimized its purification by tandem affinity chromatography. An efficient strategy for stabilization of the receptor in detergent micelles and reconstituted into lipid bilayers was developed.

11:50 Overcoming Difficult to Express Proteins: Cell-Free Additives for Solubilizing and Characterizing Membrane Proteins

Matthew ColemanMatthew Coleman, Ph.D., Deputy Group Leader, Molecular Toxicology, Lawrence Livermore National Laboratory; Senior Scientist, University of California at Davis

We have developed Cell-free methods for producing membrane proteins, which are inherently difficult to obtain. These include nanolipoprotein particles (NLPs), telodendrimers, which can be combined with NLPs or lipids, and amphipathic peptides. I will further discuss how we use the three different additives and their ability to support membrane protein solubility as well as function. These processes are easily adapted to high-throughput technologies for feeding the membrane structural biology pipeline.

12:20 pm High-Throughput Strategies for MAB and FAB Development

Leticia Reyes-Regis, Ph.D., Senior Staff Scientist, Scientific Laboratory Services Department, Pall Life Sciences

Developing a purification process using conventional methods is less and less compatible with biopharm industry challenges in terms of timelines and cost constraints. High-Throughput Process Development (HTPD) for screening chromatography sorbents and multiple process conditions, based on a Design of Experiment (DoE) approach, has become a standard that enables saving time and sample, while improving process efficiency. We will discuss mAb and Fab purification strategies leading to a three-step process set-up within 12 days.

12:50 Session Break

 1:00 Luncheon Presentation: Accurately Assessing Comparibility of Biosimilar Interferon From Refolding to Polishing During Process Development  

Belcher_PaulPaul Belcher, Ph.D., Market Development Leader, GE Healthcare Life Sciences

Developers of biosimilars use an array of biomolecular characterization methods to prove that their processes are well understood, robust, and controlled. Extensive analytical studies including comparative physicochemical and functional studies are needed to confirm similarity. This talk will describe a process for HTPD of IFNα-2a, compared throughout the development process with a market available reference molecule. The focus is on the use of Biacore™ T200 and Amersham™ WB system for accurate comparability studies during this development.

Difficult Expression and Production

2:00 Chairperson’s Remarks

Ian Hunt, Ph.D., Group Leader, Proteomic Chemistry and Head, Protein Sciences, Novartis

2:05 Designer Surfactant-Like Self-Assembling Peptides for Membrane Protein Purification and Stabilization

SotiriosKoutsopoulosSotirios Koutsopoulos, Ph.D., Research Scientist, Center for Biomedical Engineering, Massachusetts Institute of Technology

Membrane proteins are integral proteins of the cell membrane and are directly involved in the regulation of many biological functions and in drug targeting. However, our knowledge of membrane proteins is limited due to difficulties in producing sufficient quantities of soluble, functional and stable receptors. Designer, surfactant-like peptides may be used to extract the protein from the cell membrane and stabilize the protein outside the membrane bilayer for further studies.

2:35 Production of Human Integral Membrane Proteins in Mammalian Cells

JamesLoveJames D. Love, Ph.D., Director, Technology Development, Biochemistry, Albert Einstein College of Medicine

Integral membrane proteins are key targets in the understanding of health and human disease, yet producing functional material in great enough quantities for structural studies remains a formidable task. This talk highlights the expression technologies under development that will greatly aid high-throughput efforts to produce functional human membrane proteins and complexes, specifically GPCRs, for a plethora of structural techniques.

3:05 Advances for Maximizing Protein Yields in HEK293 and CHO Transient Expression

HenryChiouHenry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Increasing focus on complex proteins in advanced research elevates the need for higher yields from mammalian transient expression systems. To achieve coordinated development and synergy between novel high-capacity media, higher productivity HEK293 and CHO cells, and higher performance transfection reagents. This presentation will demonstrate the effectiveness of this “holistic” approach to achieve gram-level protein yields by transient expression.

3:35 The Need for Technology Platforms in USP Development

HugoDeWitHugo de Wit, CEO, Cellca

Are you faced with budget reductions for USP development or even anticipated to do “more with less”? Do you see increasing expectations from market and management regarding reducing timelines and cost of goods attributes? We demonstrate how a robust USP platform can help you meet these challenges.

3:50 Bypassing Inclusion Body Formation in E. coli: Maximizing Soluble Expression of Complex Multimeric Proteins

Mark Valasek, M.D., Ph.D., Co-founder and Scientific Director, AbSci

Cytoplasmic expression of large complex proteins in E. coli is limited primarily due to protein aggregation and the corresponding refolding process. These costly aggregates form when proteins are expressed too quickly and strongly. AbSci has developed a tightly regulated, dual titratable expression system that is able to homogenously induce high levels of complex multimeric proteins in a soluble and active form.

4:05 Refreshment Break

4:30 Plenary Keynote Session

From Yeast to the Brain: Advances in Proteomics (More Details >>

John YatesJohn R. Yates, Ph.D., Ernest W. Hahn Professor, Chemical Physiology and Molecular and Cellular Neurobiology, The Scripps Research Institute


5:30-7:00 Reception in the Exhibit Hall with Poster Viewing

Day 1 | Day 2 | Download Brochure | Speaker Biographies